Puma Biotech Q4 net loss $5.6M; FY net income $0; guides FY2023 product rev $205-210M

PUMA BIOTECHNOLOGY, INC.

Q4 product revenue $53.7M (+5% YoY); full year $200.0M (+6% YoY).
Q4 GAAP net loss $5.6M ($0.12/sh) vs net income $4.2M in Q4 2021; includes $12.4M legal accrual.
Full year 2022 GAAP net income $0.0M ($0.00/sh) vs net loss $29.1M in 2021.
Non-GAAP adjusted net income FY2022 $11.8M ($0.26/sh) vs $3.5M ($0.09/sh) in 2021.
FY2023 guidance: product revenue $205-210M, royalty rev $25-30M, net income $20-24M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PUMA BIOTECHNOLOGY, INC. reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue $53.7 million, net income net loss of $5.6 million, or $0.12 per share.

Period: the fourth quarter and fiscal year ended December 31, 2022
Revenue: $53.7 million
Net income: net loss of $5.6 million, or $0.12 per share
Result: reported results

Exact text from the filing

year 2021. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net for the fourth quarter of 2022 was $53.7 million, compared to $51.0 million in the fourth quarter of 2021. Product revenue, net for the full year 2022 was $200.0 million, compared to $189.1 million in 2021. Based on accounting

View on SEC.gov

Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-005220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.